#China #Suzhou #Boehringer Ingelheim #MASH #Ribo Life Science

Ribo and Boehringer Ingelheim Make Significant Progress in siRNA Program

On May 7, 2026, Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB, collectively known as Ribo, proudly announced a pivotal achievement in their collaboration with Boehringer Ingelheim. This marks the third key milestone reached in their research partnership, which is focused on developing novel treatments for liver diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH).

MASH is a severe and progressive form of fatty liver disease that poses significant health risks. It affects more than 200 million people globally and can lead to serious complications such as fibrosis, cirrhosis, liver failure, and even liver cancer. Despite its increasing prevalence, there is an urgent need for effective treatments that can slow the disease's progression and support liver health. The collaborative efforts of Ribo and Boehringer Ingelheim aim to broaden the therapeutic options available for patients suffering from MASH.

Li-Ming Gan, Co-General Manager and Global Head of Research and Development at Ribo, expressed, "This important milestone showcases the strength and maturity of our capabilities in discovering siRNA and targeted liver delivery. We take pride in how we have advanced this innovative and highly promising program together, enabling this significant breakthrough. Boehringer Ingelheim will continue to develop this program to provide new options for individuals with MASH."

The siRNA-based treatments are designed to inhibit the expression of disease-related genes by targeting their messenger RNAs. Ribo's liver-targeted delivery technology allows for selective absorption into hepatocytes, which aims to reach targets that are challenging to access using traditional small molecules or antibodies.

This milestone reflects the productivity of the collaboration between Ribo and Boehringer Ingelheim and their shared ambition to address the unmet needs in liver and cardiometabolic diseases. It underscores Ribo's status as a strategic partner for the global pharmaceutical industry, highlighting the commercial potential of its siRNA platform. Ribo is committed to advancing this collaboration and achieving further success throughout 2026 and beyond.

The implications of this development are substantial, not only for the companies involved but for millions of patients worldwide who are at risk of or suffering from MASH. By harnessing advanced biotechnology, Ribo and Boehringer Ingelheim aim to transform the treatment landscape for this debilitating condition, paving the way for improved health outcomes and quality of life for those affected.

As this program progresses, stakeholders will closely monitor its advancements, hoping for promising results that could change lives and alleviate the burden of liver disease on public health systems globally.



In conclusion, Ribo and Boehringer Ingelheim are not just achieving milestones; they are setting the stage for a future where innovative treatments for MASH can significantly alter patient experiences and outcomes. The journey is challenging, but their commitment to excellence in research and development fortifies the hope that effective therapies are on the horizon.